ISPC VS NVO Stock Comparison
Performance
ISPC10/100
10/100
ISPC returned -65.85% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NVO100/100
100/100
NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.
Sentiment
ISPC61/100
61/100
ISPC had a bullish sentiment score of 61.25% across Twitter and StockTwits over the last 12 months. It had an average of 1.00 posts, 0.00 comments, and 0.00 likes per day.
NVO
"Sentiment" not found for NVO
Technicals
ISPC21/100
21/100
ISPC receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.
NVO50/100
50/100
NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
ISPC10/100
10/100
ISPC has missed earnings 7 times in the last 20 quarters.
NVO46/100
46/100
NVO has missed earnings 3 times in the last 20 quarters.
Profit
ISPC10/100
10/100
Out of the last 17 quarters, ISPC has had 0 profitable quarters and has increased their profits year over year on 0 of them.
NVO90/100
90/100
Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.
Volatility
ISPC53/100
53/100
ISPC has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
NVO53/100
53/100
NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Analyst Price Targets
ISPC
"Analyst Price Targets" not found for ISPC
NVO50/100
50/100
1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.
All score calculations are broken down here to help you make more informed investing decisions
iSpecimen Inc. Common Stock Summary
Nasdaq / ISPC
Healthcare
Medical - Diagnostics & Research
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Novo-Nordisk A/S Summary
New York Stock Exchange / NVO
Healthcare
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ISPC to other companies in the same or a similar industry.